Novartis AG (FRA:NOT0) 5-Year RORE % : -12.88% (As of Mar. 2026)


FRA:NOT0 Novartis AG FRA:NOT0
83 GF Score
Price €18.20
GF Value €15.09
Valuation Modestly Overvalued
! 7 Warning Signs
View Full Analysis

What is Novartis AG 5-Year RORE %?

Novartis AG FRA:NOT0 83 5-Year RORE % is -12.88 as of Mar. 2026. GuruFocus rates FRA:NOT0 with a GF Score™ of 83/100 and a GF Value™ of €15.09 (Modestly Overvalued). The stock has 7 warning signs investors should review. Among 879 Drug Manufacturers companies, Novartis AG ranks worse than 78.16% on this metric.

Return on Retained Earnings (RORE) is an indicator of a company's growth potential, it shows how much a company earns by reinvesting its retained earnings, i.e. profits after dividend payments. Novartis AG's 5-Year RORE % for the quarter that ended in Mar. 2026 was -12.88%.

The industry rank for Novartis AG's 5-Year RORE % or its related term are showing as below:

FRA:NOT0's 5-Year RORE % is ranked worse than
78.16% of 879 companies
in the Drug Manufacturers industry
Industry Median: 1.37 vs FRA:NOT0: -12.88

Novartis AG  (FRA:NOT0) 5-Year RORE % Explanation

Return on Retained Earnings (RORE) is important to investors because it reveals a company's efficiency and growth potential. A higher RORE indicates a higher return. A high RORE indicates that the company should reinvest profits into the business. A lower RORE suggests that the company should distribute profits to shareholders by paying out dividends, since those dollars aren't generating much additional growth for the company.

There are a several different ways to arrive at the Return on Retained Earnings. The simplest way to calculate it is by using published information on Earnings per Share (EPS) and Dividend per Share (DPS) over a selected period. Here, 5-year period is chosen.

Be Aware

Please keep in mind that the RORE is relative to the nature of the business and its competitors. If another company in the same sector is producing a lower return on retained earnings, it doesn’t necessarily mean it’s a bad investment. It may just suggest the company is older and no longer in a high growth stage. At such a stage in the business cycle, it would be expected to see a lower RORE and higher dividend payout.


Novartis AG 5-Year RORE % Related Terms


Novartis AG 5-Year RORE % Historical Data

* Premium members only.

The historical data trend for Novartis AG's 5-Year RORE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Novartis AG 5-Year RORE % Chart

Novartis AG Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
5-Year RORE %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 26.55 -6.47 7.82 8.75 -10.68

Novartis AG Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
5-Year RORE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 11.51 10.93 10.46 -10.68 -12.88

FRA:NOT0 vs LLY, JNJ, ABBV: 5-Year RORE % Comparison

For the Drug Manufacturers - General subindustry, Novartis AG's 5-Year RORE %, along with its competitors' market caps and 5-Year RORE % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Novartis AG 5-Year RORE % vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Novartis AG's 5-Year RORE % distribution charts can be found below:

* The bar in red indicates where Novartis AG's 5-Year RORE % falls into.


FRA:NOT0
83GF Score
Novartis AG FRA:NOT0
5-Year RORE % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Novartis AG 5-Year RORE % Calculation

Novartis AG's 5-Year RORE % for the quarter that ended in Mar. 2026 is calculated as:

5-Year RORE %=( Most Recent EPS (Diluted)- First Period EPS (Diluted) )/( Cumulative EPS (Diluted) for 5-year -Cumulative Dividends per Share for 5-year )
=( 0.879-1.378 )/( 4.567-0.694 )
=-0.499/3.873
=-12.88 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of 5-Year RORE %, the most recent and first period EPS (Diluted) is the trailing twelve months (TTM) data ended in Mar. 2026 and 5-year before.

Frequently Asked Questions Learn more about 5-Year RORE % →
What does a 5-Year RORE % of -12.88 mean?
Novartis AG (FRA:NOT0) has a 5-Year RORE % of -12.88 as of Mar. 2026. 5-Year RORE % shows how much a company earns by reinvesting its retained earnings in 5-year. View historical data on Novartis AG and its competitors. According to the industry distribution chart, Novartis AG ranks #687 out of 879 companies in the Drug Manufacturers industry, placing it in the top 78.2%.
Is Novartis AG's 5-Year RORE % too high?
Novartis AG's current 5-Year RORE % is -12.88. Based on the distribution chart, Novartis AG ranks #687 out of 879 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Novartis AG has a GF Score™ of 83/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Novartis AG's 5-Year RORE % compare to LLY and JNJ?
According to the Drug Manufacturers industry distribution chart, Novartis AG ranks #687 out of 879 companies for 5-Year RORE %. This places Novartis AG in the lower half of its industry. The industry median 5-Year RORE % is 1.37. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 5-Year RORE % for a Drug Manufacturers company?
The median 5-Year RORE % among Drug Manufacturers companies is 1.37, based on 879 companies in the industry. Companies in the top quartile (top 25%) have a 5-Year RORE % significantly above this median, while those in the bottom quartile fall well below. However, 5-Year RORE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 5-Year RORE % mean?
A high 5-Year RORE % can signal that a stock is expensive relative to its fundamentals. 5-Year RORE % shows how much a company earns by reinvesting its retained earnings in 5-year. View historical data on Novartis AG and its competitors. For the Drug Manufacturers industry, the median 5-Year RORE % is 1.37 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Novartis AG's current 5-Year RORE % is -12.88. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Novartis AG stock overvalued right now?
Based on GuruFocus' analysis, Novartis AG (FRA:NOT0) is currently considered Modestly Overvalued. The stock's GF Value™ is €15.09, compared to a current price of €18.20 — trading 20.6% above its estimated fair value. The current 5-Year RORE % is -12.88. Novartis AG's overall GF Score™ is 83/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 5-Year RORE % calculated?
5-Year RORE % is calculated from a company's financial statements. For Novartis AG (FRA:NOT0), the current 5-Year RORE % is -12.88 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Novartis AG (FRA:NOT0) Overvalued in 2026?

Based on GuruFocus' analysis, Novartis AG stock appears to be overvalued. The current stock price of €18.20 is trading 20.6% above its estimated GF Value™ of €15.09. GuruFocus considers Novartis AG to be Modestly Overvalued.

Key valuation signals for FRA:NOT0:

  • 5-Year RORE %: -12.88
  • GF Value™: €15.09 vs. price of €18.20 (20.6% above fair value)
  • GF Score™: 83/100 with 7 warning signs

No single metric tells the full story. See the FRA:NOT0 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Novartis AG Business Description

Address Lichtstrasse 35, Basel, CHE, 4056
Novartis develops and manufactures innovative drugs. Key areas of drug development are oncology, immunology, neuroscience, respiratory, and cardiovascular, renal, and metabolic. It also has an established medicines business, which includes off-patent franchises. The company sells its products globally, with the United States constituting close to one-third of total revenue.
83GF Score

Get the complete analysis for FRA:NOT0

5-Year RORE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€18.20
Price
€15.09
GF Value